DelveInsight’s “Hydrocephalus Drugs Market Insights, Epidemiology, and Market Forecast-2034” report offers an in-depth understanding of Hydrocephalus, historical and forecasted epidemiology, as well as the Hydrocephalus market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
To know in detail about the Hydrocephalus market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Hydrocephalus Market Forecast
Some of the key facts of the Hydrocephalus Market Report:
- In April 2025, CereVasc received its second FDA Breakthrough Device Designation, this time for its investigational eShunt System in the treatment of communicating hydrocephalus in pediatric patients aged 12 and older, supported by pilot clinical data and findings published in the Journal of NeuroInterventional Surgery.
- The Hydrocephalus market is expected to strengthen over the 2020–2034 study period as disease awareness increases and more effective interventions reach patients across the 7MM — the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
- Precise 2023 market size figures and the forecast CAGR through 2034 are available in the full report.
- The Hydrocephalus treatment landscape remains largely device- and device-adjacent, with therapeutic development anchored in shunt systems and related neurosurgical technologies rather than a conventional drug pipeline.
- The report’s pipeline segment tracks candidates in Phase II and Phase III development, alongside company-level insights into collaborations, licensing activity, and patent details shaping the emerging Hydrocephalus treatment landscape.
- Rising healthcare spending and growing disease awareness worldwide are expected to expand the addressable market and support broader manufacturer penetration over the forecast period.
- Key Hydrocephalus Companies: DePuy Synthes, Boston Neurosciences, Medtronic Plc, Integra Life Sciences Corporation, Spiegelberg GmbH & Co. KG, RAUMEDIC Inc., Sophysa SA, Terumo Corporation, Natus Medical Incorporated, Johnson & Johnson Services, and others.
- The Hydrocephalus market is expected to witness a major shift over the study period as a better understanding of disease pathogenesis contributes to the development of novel therapeutics and device-based approaches.
Hydrocephalus Overview
Hydrocephalus is a neurological condition marked by an abnormal accumulation of cerebrospinal fluid (CSF) within the brain’s ventricular system, leading to increased intracranial pressure. It can arise from a range of causes, including congenital malformations, infections, hemorrhage, tumors, or trauma that obstruct or impair CSF flow and absorption. Presentation varies by age and underlying cause, and diagnosis typically relies on clinical evaluation supported by neuroimaging. Management has traditionally centered on surgical intervention — most commonly CSF shunting or endoscopic third ventriculostomy — to relieve pressure and restore normal fluid dynamics, with device manufacturers continuing to refine shunt systems and monitoring technologies to improve safety, durability, and patient outcomes.
Get a Free sample for the Hydrocephalus Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/hydrocephalus-market
Hydrocephalus Epidemiology
The Hydrocephalus epidemiology section provides insights into the historical, current, and forecasted patient pool across the seven major markets (7MM) — the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan — for the 2020–2034 study period. It draws on published studies and key opinion leader input to explain current and forecasted trends, along with a detailed country-wise breakdown of the diagnosed patient pool and the assumptions underlying it.
Download the report to understand which factors are driving Hydrocephalus epidemiology trends @ Hydrocephalus Prevalence
Hydrocephalus Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of adoption of Hydrocephalus therapies recently launched or expected to launch during the 2020–2034 study period, covering market uptake by drug, patient uptake by therapy, and per-drug sales — insights that support comparison of market share and size across therapies and inform financial and regulatory decision-making.
The report’s pipeline segment covers therapeutic candidates in Phase II and Phase III development, along with details on collaborations, acquisitions, mergers, licensing, and patents shaping the Hydrocephalus emerging therapy landscape.
Hydrocephalus Key Companies
- DePuy Synthes
- Boston Neurosciences
- Medtronic Plc
- Integra Life Sciences Corporation
- Spiegelberg GmbH & Co. KG
- RAUMEDIC Inc.
- Sophysa SA
- Terumo Corporation
- Natus Medical Incorporated
- Johnson & Johnson Services
- and others
Discover more about therapies and devices set to shape the Hydrocephalus market @ Hydrocephalus Treatment Landscape
Hydrocephalus Market Drivers
- Rising Disease Awareness: Growing awareness of Hydrocephalus among patients and clinicians is expected to support earlier diagnosis and broader treatment uptake.
- Incremental Healthcare Spending: Rising healthcare expenditure across the 7MM is expected to expand market size and enable greater manufacturer penetration.
- Device and Technology Innovation: Continued refinement of shunt systems and investigational technologies, such as CereVasc’s eShunt System, reflects ongoing innovation aimed at improving safety and outcomes.
- Improving Understanding of Disease Pathogenesis: A deeper understanding of the underlying mechanisms of Hydrocephalus is expected to support the development of novel therapeutics and treatment approaches.
- Regulatory Support for Novel Devices: Designations such as the FDA’s Breakthrough Device Designation are helping accelerate the development and review of promising new interventions.
Hydrocephalus Market Barriers
- Limited Late-Stage Pipeline: The Hydrocephalus pipeline remains concentrated in early-to-mid-stage development, with relatively few late-stage (Phase III) candidates advancing toward approval.
- Reliance on Surgical/Device-Based Management: With no broadly established pharmacologic disease-modifying therapy, treatment continues to depend heavily on surgical shunting and device-based approaches, each carrying procedural risk and long-term complication potential.
- Reimbursement Complexity: Reimbursement barriers vary significantly by market, requiring careful navigation of country-specific access and pricing strategies.
- Diagnostic and Etiological Heterogeneity: The wide range of underlying causes and presentations of Hydrocephalus complicates standardized diagnosis and treatment planning across patient populations.
Scope of the Hydrocephalus Market Report
- Study Period: 2020–2034
- Coverage: 7MM
- Key Hydrocephalus Companies: DePuy Synthes, Boston Neurosciences, Medtronic Plc, Integra Life Sciences Corporation, Spiegelberg GmbH & Co. KG, RAUMEDIC Inc., Sophysa SA, Terumo Corporation, Natus Medical Incorporated, Johnson & Johnson Services, and others
- Hydrocephalus Therapeutic Assessment: Hydrocephalus current marketed and Hydrocephalus emerging therapies
- Hydrocephalus Market Dynamics: Hydrocephalus market drivers and Hydrocephalus market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s Five Forces, BCG Matrix, Market entry strategies
- Hydrocephalus Unmet Needs, KOL’s views, Analyst’s views, Market Access and Reimbursement
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, benefiting market analysis to accelerate business growth and overcome challenges with a practical approach.
Contact Us
Kanishk
